Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

Argatoff, 1997, Mantle cell lymphoma: a clinicopathologic study of 80 cases, Blood, 89, 2067, 10.1182/blood.V89.6.2067 Velders, 1996, Mantle-cell lymphoma: a population-based clinical study, J Clin Oncol, 14, 1269, 10.1200/JCO.1996.14.4.1269 1997, A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project, Blood, 89, 3909, 10.1182/blood.V89.11.3909 Zhou, 2008, Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004, Cancer, 113, 791, 10.1002/cncr.23608 Geisler, 2009, Mantle cell lymphoma—does primary intensive immunochemotherapy improve overall survival for younger patients?, Leuk Lymphoma, 50, 1249, 10.1080/10428190903040030 Herrmann, 2009, Improvement of overall survival in advanced stage mantle cell lymphoma, J Clin Oncol, 27, 511, 10.1200/JCO.2008.16.8435 Geisler, 2008, Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group, Blood, 112, 2687, 10.1182/blood-2008-03-147025 Romaguera, 2010, Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma, Br J Haematol, 150, 200 Dietrich, 2010, Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma, Cancer Witzig, 2005, Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma, J Clin Oncol, 23, 5347, 10.1200/JCO.2005.13.466 Ansell, 2008, Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group, Cancer, 113, 508, 10.1002/cncr.23580 Huang, 2003, Rapamycins: mechanism of action and cellular resistance, Cancer Biol Ther, 2, 222, 10.4161/cbt.2.3.360 Dudkin, 2001, Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition, Clin Cancer Res, 7, 1758 Vivanco, 2002, The phosphatidylinositol 3-kinase AKT pathway in human cancer, Nat Rev Cancer, 2, 489, 10.1038/nrc839 Gera, 2004, AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression, J Biol Chem, 279, 2737, 10.1074/jbc.M309999200 Noh, 2004, Determinants of rapamycin sensitivity in breast cancer cells, Clin Cancer Res, 10, 1013, 10.1158/1078-0432.CCR-03-0043 Hidalgo, 2000, The rapamycin-sensitive signal transduction pathway as a target for cancer therapy, Oncogene, 19, 6680, 10.1038/sj.onc.1204091 Farag, 2009, Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma, Leuk Res, 33, 1475, 10.1016/j.leukres.2009.01.039 Hess, 2009, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma, J Clin Oncol, 27, 3822, 10.1200/JCO.2008.20.7977 Foran, 2000, European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma, J Clin Oncol, 18, 317, 10.1200/JCO.2000.18.2.317 Ghielmini, 2005, Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK), J Clin Oncol, 23, 705, 10.1200/JCO.2005.04.164 Coiffier, 1998, Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study, Blood, 92, 1927 Shan, 2000, Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells, Cancer Immunol Immunother, 48, 673, 10.1007/s002620050016 Golay, 2000, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis, Blood, 95, 3900, 10.1182/blood.V95.12.3900 Wurflein, 1998, Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells, Cancer Res, 58, 3051 Jazirehi, 2004, Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab, Cancer Res, 64, 7117, 10.1158/0008-5472.CAN-03-3500 Kanelli, 2001, Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis, Leuk Lymphoma, 42, 1329, 10.1080/10428190127502 Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 Smith, 2010, Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium, J Clin Oncol, 28, 4740, 10.1200/JCO.2010.29.2813 Gupta, 2009, Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2, Blood, 114, 2926, 10.1182/blood-2009-05-220889